Short- and Intermediate-Term Results of 32 P Radioactive β-Emitting Stent Implantation in Patients With Coronary Artery Disease

Publisher Website
Google Scholar
Abstract
Background—Radioactive 32P β-emitting stents have been shown to reduce intrastent neointimal hyperplasia in a substantial dose-related manner in the animal model. The aim of this dose-response study was to evaluate, in the clinical setting, the safety and efficacy at 6-month follow-up of this approach to reducing restenosis. Methods and Results—A total of 122 32P radioactive β-emitting stents (initially the Palmaz-Schatz and later the BX Isostent) with an activity level of 0.75 to 3.0 μCi (group 1), 3.0 to 6.0 μCi (group 2), and 6.0 to 12.0 μCi (group 3) were implanted in 91 lesions in 82 patients. There were no procedural events. At 6-month follow-up, no deaths had occurred, and only 1 patient had stent thrombosis. Pure intrastent binary restenosis was 16% in group 1, 3% in group 2, and 0% in group 3. However, intralesion restenosis was 52% in group 1, 41% in group 2, and 50% in group 3. Conclusions—The use of 32P radioactive β-emitting stents in patients with CAD is feasible. At 6-month follow-up, intra...